I completely agree with your analysis. NP's number one priority right now is completing enrollment in the 75 patient phase 2 trial; he basically said that in the investors' cc two Mondays ago. This is the lane that Leronlimab can have all to itself, while Remdesevir has the severely ill patient lane all to itself (for the time being).